ストックスクリーナーアプリを入手
0.7623
0.70%
-0.0054
アフターアワーズ：
.73
-0.0323
-4.24%
前日終値:
$0.7677
開ける：
$0.7899
24時間の取引高:
15,056
Relative Volume:
0.14
時価総額：
$13.39M
収益：
$52.58M
当期純損益:
$-3.28M
株価収益率:
-3.9559
EPS:
-0.1927
ネットキャッシュフロー:
$-2.53M
1週間 パフォーマンス:
-7.54%
1か月 パフォーマンス:
+19.95%
6か月 パフォーマンス:
-27.40%
1年 パフォーマンス:
-28.08%
1日の値動き範囲:
$0.75
$0.7899
1週間の範囲:
$0.75
$0.8355
52週間の値動き範囲:
$0.607
$1.6481
Iridex Corp Stock (IRIX) Company Profile
Compare IRIX vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRIX
Iridex Corp
|
0.7623 | 13.39M | 52.58M | -3.28M | -2.53M | -0.1927 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Iridex Corp Stock (IRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-11-03 | 再開されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | ROTH Capital | Buy |
| 2016-01-26 | 開始されました | Singular Research | Buy |
| 2007-01-03 | 開始されました | First Albany | Buy |
Iridex Corp (IRIX) 最新ニュース
Form 4 IRIDEX Corporation: Novel Inspiration International Co., Ltd. (10% Owner) For: 2 October - Investing.com India
Novel Inspiration International Acquires 146,313 IRIDEX Shares as Convertible Note Interest Payment - Kalkine Media
A 10% owner acquires 146,313 IRIDEX (IRIX) shares as quarterly note interest. - Stock Titan
Form 4 IRIDEX Corporation: Patrick Mercer (Director, President and CEO) For: 1 October - Investing.com Canada
Iridex study shows two-year glaucoma treatment outcomes - Investing.com
Iridex reports 2-year glaucoma study shows sustained IOP reduction - Investing.com
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma - GlobeNewswire Inc.
A glaucoma laser treatment lowered eye pressure and medicine use over two years. - Stock Titan
Iridex Announces the Publication of Two-Year Independent - GlobeNewswire
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma - Yahoo Finance
Iridex Corporation Announces Publication of Two-Year Clinical Study Demonstrating Favorable Outcomes with Micropulse TLT in Patients with Early, Moderate, and Advanced Primary Glaucoma - www.marketscreener.com
Iridex director Lin Shih-Yao David buys $438,762 in stock By Investing.com - Investing.com Nigeria
Iridex director Lin Shih-Yao David buys $273,611 in company stock - Investing.com
Iridex director David Lin’s entity buys $597,902 in common stock - Investing.com
Iridex director Lin Shih-Yao David buys $438,762 in stock - Investing.com
Form 4 IRIDEX Corporation For: 7 October By Investing.com - Investing.com Nigeria
Form 4 IRIDEX Corporation For: 7 October By Investing.com - Investing.com India
One investor makes 30 open-market purchases of IRIDEX (IRIX) shares. - Stock Titan
Iridex Insider Bought Shares Worth $597,903, According to a Recent SEC Filing - www.marketscreener.com
A 10% owner's firm buys IRIDEX (IRIX) shares in 30 open-market transactions. - Stock Titan
A 10% owner reports 30 previously unreported IRIDEX (IRIX) purchases by Xinpo. - Stock Titan
Iridex Corporation Completes Relocation of Manufacturing Facility to San Jose, California - marketscreener.com
After delivering or withholding 23,917 shares, IRIDEX (IRIX) CEO holds 444,867 shares directly. - Stock Titan
Iridex Completes Relocation of Manufacturing Facility to San Jose, California - Yahoo Finance
Iridex Corp (IRIX-Q) Stock Price and News - theglobeandmail.com
IRIDEX (IRIX) CFO buys 7,900 more shares - stocktitan.net
IRIDEX (IRIX) CFO adds 2,354 shares in open-market buy - stocktitan.net
CFO now holds 175,052 shares after Iridex Corp (IRIX) stock buy - stocktitan.net
IRIDEX Received Notice of Noncompliance - tradingview.com
IRIDEX (NASDAQ:IRIX): What Is Driving Penny Stock Attention? - Kalkine Media
IRIDEX (NASDAQ:IRIX): Is Clinical Demand Building Momentum? - kalkinemedia.com
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15% - Yahoo Finance
IRIDEX (IRIX) CFO adds 6,668 shares in open-market buys - Stock Titan
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 - GuruFocus
IRIX Looks 45.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive - Investing.com South Africa
IRIDEX Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Is IRIDEX Corp (IRIX) Positioned for Growth After Q2 Earnings Mi - GuruFocus
IRIDEX Q2 Revenue Falls 7% as Retina Weakness Offsets Glaucoma Growth - minichart.com.sg
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com Canada
Full Transcript: Iridex Q2 2026 Earnings Call - Benzinga
Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive - Investing.com
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com Australia
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com UK
IRIDEX Corp reports results for the quarter ended June 30Earnings Summary - TradingView
IRIDEX CORP Q2 2026: Revenue $12.6M, EPS $(0.07) — 10-Q Summary - TradingView
IRIDEX (IRIX) glaucoma sales rise as retina revenue falls - Stock Titan
IRIDEX earnings missed by $0.05, revenue fell short of estimates - Investing.com
Iridex Reports Q2 2026 Revenue $12.6M, Net Loss $1.3M; Cyclo G6 Probe Growth Boosts Glaucoma Sales - TradingView
Iridex falls short on Q2 revenue and earnings expectations By Investing.com - Investing.com Australia
Iridex Corp (IRIX) 財務データ
収益
当期純利益
現金流量
EPS
Iridex Corp (IRIX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dizon Romeo R | Chief Financial Officer |
Sep 16 '26 |
Buy |
0.63 |
7,900 |
4,977 |
185,306 |
| Dizon Romeo R | Chief Financial Officer |
Sep 14 '26 |
Buy |
0.65 |
2,354 |
1,530 |
177,406 |
| Dizon Romeo R | Chief Financial Officer |
Sep 10 '26 |
Buy |
0.68 |
5,100 |
3,468 |
175,052 |
| Dizon Romeo R | Chief Financial Officer |
Aug 24 '26 |
Buy |
0.75 |
6,668 |
4,999 |
169,952 |
| Dizon Romeo R | Chief Financial Officer |
Jun 12 '26 |
Buy |
1.14 |
975 |
1,110 |
135,975 |
| Dizon Romeo R | Chief Financial Officer |
Jun 11 '26 |
Buy |
1.14 |
1,675 |
1,909 |
135,000 |
| Dizon Romeo R | Chief Financial Officer |
Jun 08 '26 |
Buy |
1.12 |
2,400 |
2,688 |
133,325 |
| Dizon Romeo R | Chief Financial Officer |
Jun 05 '26 |
Buy |
1.15 |
2,521 |
2,899 |
130,925 |
| Dizon Romeo R | Chief Financial Officer |
Jun 03 '26 |
Buy |
1.17 |
2,400 |
2,808 |
128,404 |
| Dizon Romeo R | Chief Financial Officer |
May 26 '26 |
Buy |
1.00 |
5,004 |
5,004 |
126,004 |
5.75%
大文字化:
|
ボリューム (24 時間):